Janssen files Darzalex Faspro for rare disease light chain amyloidosis

Johnson & Johnson’s pharmaceuticals unit said it had filed Darzalex Faspro (daratumumab+hyaluronidase), a subcutaneous formulation of the drug already approved in several blood cancers.